Eton Pharmaceuticals Inc. (ETON) Misses Q3 EPS by 7c

Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q3 EPS of $0.04, $0.07 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $22.5 million versus the consensus estimate of $20.27 million.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.

You May Also Be Interested In

• Citi upgrades Bath & Body Works to Buy with $25 price target
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
• KeyBanc Upgrades Acadia Realty Trust (AKR) to Overweight